Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
暂无分享,去创建一个
William J Savage | B. Yawn | A. Horton | P. Tanabe | R. Ware | A. James | S. Ballas | E. Ortiz | W. Savage | S. Lanzkron | Samir K Ballas | K. Hassell | G. Buchanan | Barbara P Yawn | L. Jordan | Andra H James | J. Goldsmith | George R Buchanan | Russell E Ware | M Hassan Murad | Eduardo Ortiz | Richard Lottenberg | Araba N Afenyi-Annan | Kathryn L Hassell | Lanetta Jordan | Sophie M Lanzkron | Paula J Tanabe | Jonathan C Goldsmith | Robinson Fulwood | Ann Horton | Joylene John-Sowah | R. Lottenberg | M. H. Murad | A. Afenyi‐Annan | Joylene John-Sowah | R. Fulwood | Jonathan C. Goldsmith
[1] Jeremy Grimshaw,et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. , 2009, Journal of clinical epidemiology.
[2] Eufemia Jacob,et al. Are there phases to the vaso-occlusive painful episode in sickle cell disease? , 2005, Journal of pain and symptom management.
[3] E. Terpos,et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). , 2010, Blood.
[4] S. Charache,et al. "Acute chest syndrome" in adults with sickle cell anemia. Microbiology, treatment, and prevention. , 1979, Archives of internal medicine.
[5] R. Ware,et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. , 2004, The Journal of pediatrics.
[6] E Vichinsky,et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. , 1986, The New England journal of medicine.
[7] B. Pollock,et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. , 2008, Annals of internal medicine.
[8] K. Curtis,et al. U.S. medical eligibility criteria for contraceptive use, 2010. , 2010, Journal of women's health.
[9] Samuel F Posner,et al. Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[10] M. Gladwin,et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. , 2014, American journal of respiratory and critical care medicine.
[11] Howard Balshem,et al. GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.
[12] J. Stockman. Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease , 2011 .
[13] Rm,et al. Sickle cell disease , 1996 .
[14] D. Strbian,et al. Sickle cell disease and stroke. , 2014, Stroke.
[15] R. Shukla,et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. , 1995, The New England journal of medicine.
[16] J. Guillebaud,et al. Medical eligibility criteria for contraceptive use , 2018, Advanced Health Assessment of Women.
[17] Scott T. Miller,et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG) , 2011, The Lancet.
[18] K. Ataga,et al. Renal abnormalities in sickle cell disease , 2000, American journal of hematology.
[19] R. Adams,et al. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. , 2005, The New England journal of medicine.
[20] E. Spackman,et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial , 2013, The Lancet.
[21] Scott T. Miller,et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. , 1998, The New England journal of medicine.
[22] J. Stockman,et al. A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease , 2013 .
[23] P. V. Ichinsky,et al. Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease , 2000 .
[24] J. Niland,et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. , 1991, Annals of internal medicine.
[25] R. Ichord,et al. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. , 2010, The Journal of pediatrics.
[26] M. Steinberg. Hydroxyurea Treatment for Sickle Cell Disease , 2002, TheScientificWorldJournal.
[27] C. Danielson. The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[28] John D. Roberts,et al. Daily Assessment of Pain in Adults with Sickle Cell Disease , 2008, Annals of Internal Medicine.
[29] C. Dampier,et al. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. , 2002, The journal of pain : official journal of the American Pain Society.
[30] Renee F Wilson,et al. Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease , 2008, Annals of Internal Medicine.
[31] Jiaquan Xu,et al. Deaths: preliminary data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[32] L. Benjamin,et al. Definitions of the phenotypic manifestations of sickle cell disease , 2009, American journal of hematology.
[33] Scott T. Miller,et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. , 2001, The Journal of pediatrics.
[34] S. Sheth,et al. Sickle cell disease: time for a closer look at treatment options? , 2013, British journal of haematology.
[35] L. Sleeper,et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. , 1991, The New England journal of medicine.
[36] J. Powell,et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. , 2014, JAMA.
[37] Renee F Wilson,et al. Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children , 2008, Pediatrics.
[38] R. Chou,et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. , 2009, The journal of pain : official journal of the American Pain Society.
[39] A. James,et al. Morbidity associated with sickle cell disease in pregnancy. , 2006, American journal of obstetrics and gynecology.
[40] R. Ware,et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. , 2004, Blood.
[41] M L Terrin,et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.
[42] S. Obaro,et al. Infection in sickle cell disease: a review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[43] N. Mohandas,et al. Sickle Red Cell Microrheology and Sickle Blood Rheology , 2004, Microcirculation.
[44] C. Whitney,et al. Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.
[45] S. Dertinger,et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. , 2009, Mutation research.
[46] H. Bunn. Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.
[47] G. Guyatt,et al. The Endocrine Society guidelines: when the confidence cart goes before the evidence horse. , 2013, The Journal of clinical endocrinology and metabolism.
[48] R. Ware. How I use hydroxyurea to treat young patients with sickle cell anemia. , 2010, Blood.
[49] Susan Michie,et al. Investigating complexity in systematic reviews of interventions by using a spectrum of methods. , 2013, Journal of clinical epidemiology.
[50] B. Moriarty,et al. Patterns of visual loss in untreated sickle cell retinopathy , 1988, Eye.
[51] S. Ballas,et al. Sickle cell pain: a critical reappraisal. , 1998, Blood.
[52] C. Pegelow,et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.
[53] J. Herrick,et al. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. , 2014, JAMA.
[54] R. Ware,et al. Chromosome damage and repair in children with sickle cell anaemia and long‐term hydroxycarbamide exposure , 2011, British journal of haematology.
[55] G. Pasternak,et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. , 2009, The journal of pain : official journal of the American Pain Society.
[56] J. Freedman,et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease , 1996 .
[57] Julie Morris,et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial--the priapism in sickle cell study. , 2011, Journal of andrology.
[58] S. Ballas,et al. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance , 2005, American journal of hematology.
[59] P. Lane. Sickle cell disease. , 1996, Pediatric clinics of North America.
[60] C. J. Wang,et al. Management of Children With Sickle Cell Disease: A Comprehensive Review of the Literature , 2011, Pediatrics.
[61] B. Aygun,et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions , 2002, Transfusion.
[62] S. Chou. Transfusion therapy for sickle cell disease: a balancing act. , 2013, Hematology. American Society of Hematology. Education Program.
[63] M. Buchowski,et al. The relationship of oxygen transport and cardiac index for the prevention of sickle cell crises. , 2010, Journal of the National Medical Association.
[64] S. Sivaprasad,et al. Sickle cell disease and the eye: old and new concepts. , 2010, Survey of ophthalmology.
[65] S Kamen,et al. The task force. , 1976, Journal of hospital dental practice.
[66] D. Bachir,et al. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen , 2011, Orphanet journal of rare diseases.
[67] J. Scott,et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. , 2003, Pediatrics.
[68] D. Barradas,et al. Sickle cell disease and pregnancy outcomes: women of African descent. , 2010, American journal of preventive medicine.
[69] S. King. Nitric oxide production from hydroxyurea. , 2004, Free radical biology & medicine.
[70] Harold Lehmann,et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. , 2014, The New England journal of medicine.
[71] H. Schünemann,et al. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). , 2011, Vaccine.